Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 25304031)

  • 21. Transcriptome profiling-based identification of prognostic subtypes and multi-omics signatures of glioblastoma.
    Park J; Shim JK; Yoon SJ; Kim SH; Chang JH; Kang SG
    Sci Rep; 2019 Jul; 9(1):10555. PubMed ID: 31332251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of the EGFR Amplification and CDKN2A Deletion Regulated Transcriptomic Signatures Reveals the Prognostic Significance of
    Wang H; Wang X; Xu L; Zhang J; Cao H
    Front Oncol; 2021; 11():551160. PubMed ID: 33959491
    [No Abstract]   [Full Text] [Related]  

  • 23. Overexpression of FoxO3a is associated with glioblastoma progression and predicts poor patient prognosis.
    Qian Z; Ren L; Wu D; Yang X; Zhou Z; Nie Q; Jiang G; Xue S; Weng W; Qiu Y; Lin Y
    Int J Cancer; 2017 Jun; 140(12):2792-2804. PubMed ID: 28295288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis.
    Kim YW; Koul D; Kim SH; Lucio-Eterovic AK; Freire PR; Yao J; Wang J; Almeida JS; Aldape K; Yung WK
    Neuro Oncol; 2013 Jul; 15(7):829-39. PubMed ID: 23502430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Glucose Metabolism-Related Gene Signature for Overall Survival Prediction in Patients with Glioblastoma.
    Zhang C; Wang M; Ji F; Peng Y; Wang B; Zhao J; Wu J; Zhao H
    Biomed Res Int; 2021; 2021():8872977. PubMed ID: 33553434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
    Murnyák B; Kouhsari MC; Hershkovitch R; Kálmán B; Marko-Varga G; Klekner Á; Hortobágyi T
    Oncotarget; 2017 Jul; 8(28):46348-46362. PubMed ID: 28654422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A RNA sequencing-based six-gene signature for survival prediction in patients with glioblastoma.
    Zuo S; Zhang X; Wang L
    Sci Rep; 2019 Feb; 9(1):2615. PubMed ID: 30796273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma.
    Li Q; Chen B; Cai J; Sun Y; Wang G; Li Y; Li R; Feng Y; Han B; Li J; Tian Y; Yi L; Jiang C
    PLoS One; 2016; 11(3):e0151815. PubMed ID: 27022952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L1 expression and prognostic impact in glioblastoma.
    Nduom EK; Wei J; Yaghi NK; Huang N; Kong LY; Gabrusiewicz K; Ling X; Zhou S; Ivan C; Chen JQ; Burks JK; Fuller GN; Calin GA; Conrad CA; Creasy C; Ritthipichai K; Radvanyi L; Heimberger AB
    Neuro Oncol; 2016 Feb; 18(2):195-205. PubMed ID: 26323609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positive Expression of Retinol-Binding Protein 4 Is Related to the Malignant Clinical Features Leading to Poor Prognosis of Glioblastoma.
    Deng X; Ren J; Bi Z; Fu Z
    Genet Res (Camb); 2022; 2022():5435523. PubMed ID: 36632438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
    Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
    Liang Y; Bollen AW; Aldape KD; Gupta N
    BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma.
    Liu B; Liu J; Liao Y; Jin C; Zhang Z; Zhao J; Liu K; Huang H; Cao H; Cheng Q
    Med Sci Monit; 2019 May; 25():3624-3635. PubMed ID: 31094363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of tumor growth via IGFBP3 depletion as a potential treatment in glioma.
    Chen CH; Chen PY; Lin YY; Feng LY; Chen SH; Chen CY; Huang YC; Huang CY; Jung SM; Chen LY; Wei KC
    J Neurosurg; 2019 Jan; 132(1):168-179. PubMed ID: 30641835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establish six-gene prognostic model for glioblastoma based on multi-omics data of TCGA database.
    Lei CG; Jia XY; Sun WJ
    Yi Chuan; 2021 Jul; 43(7):665-679. PubMed ID: 34284982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mesenchymal and Proneural Subtypes of Glioblastoma Disclose Branching Based on GSC Associated Signature.
    Steponaitis G; Tamasauskas A
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LINC00174 is a favorable prognostic biomarker in glioblastoma via promoting proliferative phenotype.
    Wang Z; Wang Q; Bao Z; Guo L; Chen H; Lv T; Xu T; Zhang X; Zhou C; Sun L
    Cancer Biomark; 2020; 28(4):421-427. PubMed ID: 32390602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma.
    Cheng W; Zhang C; Ren X; Jiang Y; Han S; Liu Y; Cai J; Li M; Wang K; Liu Y; Hu H; Li Q; Yang P; Bao Z; Wu A
    J Neurosurg; 2017 Jan; 126(1):249-259. PubMed ID: 26967788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Large-Scale Analysis Reveals Gene Signature for Survival Prediction in Primary Glioblastoma.
    Prasad B; Tian Y; Li X
    Mol Neurobiol; 2020 Dec; 57(12):5235-5246. PubMed ID: 32875483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive analysis of PSMD family members and validation of PSMD9 as a potential therapeutic target in human glioblastoma.
    Li Y; Liu X; Zhao F; Zhao Z; Li X; Wang J; Huang B; Chen A
    CNS Neurosci Ther; 2024 Feb; 30(2):e14366. PubMed ID: 37485655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.